James M. Cleary

Abstract B110: Effector CD4 T cells convert transient responses to KRAS targeted therapy into long-term durable remissions in pancreatic cancer

Pancreatic ductal adenocarcinoma is refractory to most therapies, including immunotherapies, where reinvigoration of CD8 T cells with immune checkpoint blockade is insufficient to induce long-term durable remissions. Direct inhibitors of KRAS are clinically promising, although acquired resistance is common. To test i...